Literature DB >> 11552023

Determinants of overall quality of life in secondary progressive MS: a longitudinal study.

P O'Connor1, L Lee, P T Ng, P Narayana, J S Wolinsky.   

Abstract

Twenty-nine patients with secondary progressive MS underwent monthly assessment with Expanded Disability Status Scale (EDSS), MS Functional Composite (MSFC), MS Quality of Life-54, and cranial MRI over 6 months. Overall quality of life (OQOL) correlated highly with emotional well-being, the mental health composite, health distress, and the physical health composite. In contrast, there was no statistical evidence of consistent correlation between OQOL and EDSS, MSFC, or MR outcome measures.

Entities:  

Mesh:

Year:  2001        PMID: 11552023     DOI: 10.1212/wnl.57.5.889

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Walking speed and health-related quality of life in multiple sclerosis.

Authors:  Christine G Kohn; William L Baker; Matthew F Sidovar; Craig I Coleman
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 2.  [Quality of life in multiple sclerosis. Measures, relevance, problems, and perspectives].

Authors:  W Pöllmann; C Busch; R Voltz
Journal:  Nervenarzt       Date:  2005-02       Impact factor: 1.214

3.  Home based management in multiple sclerosis: results of a randomised controlled trial.

Authors:  C Pozzilli; M Brunetti; A M V Amicosante; C Gasperini; G Ristori; L Palmisano; M Battaglia
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-09       Impact factor: 10.154

4.  Contribution of symptom clusters to multiple sclerosis consequences.

Authors:  Shahnaz Shahrbanian; Pierre Duquette; Ayse Kuspinar; Nancy E Mayo
Journal:  Qual Life Res       Date:  2014-09-17       Impact factor: 4.147

5.  Quality of life in multiple sclerosis: translation in French Canadian of the MSQoL-54.

Authors:  Catherine Acquadro; Louise Lafortune; Isabelle Mear
Journal:  Health Qual Life Outcomes       Date:  2003-11-24       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.